The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: Implication in the clinical decision-making

Current Medicinal Chemistry

Volumn 17, Issue 11, 2010, Pages 1030-1038

  Rossi, A ^a   Maione, P ^a   Bareschino, M A ^a   Schettino, C ^a   Sacco, P C ^a   Ferrara, M L ^b   Castaldo, V ^a   Gridelli, C ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bevacizumab; Chemotherapy; Figitumumab; First line therapy; Histology based therapy; NSCLC; Pemetrexed; Sorafenib

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CP 751871; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CARCINOGENESIS; CLINICAL DECISION MAKING; CLINICAL TRIAL; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; HEMOPTYSIS; HISTOLOGY; HUMAN; HYPERGLYCEMIA; LARGE CELL CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; VEIN THROMBOSIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 77950655175     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790820589     Document Type: Review

References (51)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics. CA. Cancer J. Clin., 2009, 59, 225-249.
2. Socinski, M.A.; Crowell, R.; Hensing, T.E.; Langer, C.J.; Lilenbaum, R.; Sandler, A.B.; Morris, D. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest, 2007, 132, 277-289 (Pubitemid 47494408)
3. Waters, J.S.; O'Brien, M.E.R. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE). Br. J. Cancer, 2002, 87, 481-490
4. Schiller, J.H.; Harrington, D.; Belani, C.P.; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med., 2002, 346, 92-98 (Pubitemid 34438899)
5. Gabrielson, E. Worldwide trends in lung cancer pathology. Respirology, 2006, 11, 533-538 (Pubitemid 44186257)
6. Strauss, G.M.; Jemal, A.; McKenna, M.B.; Strauss, J.A.; Cummings, K.M. The epidemic of smoking-related adenocarcinoma of the lung: the role of the tobacco industry and filtered and low-tar cigarettes. J. Thorac. Oncol., 2007, 2 (Suppl. 4), S305 (abstr. PRS-01).
7. Scagliotti, G.V.; Parikh, P.; von Pawel, J.; Biesma, B.; Vansteenkiste, J.; Manegold, C.; Serwatowski, P.; Gatzemeier, U.; Digumarti, R.; Zukin, M.; Lee, J.S.; Mellemgaard, A.; Park, K.; Patil, S.; Rolski, J.; Goksel, T.; de Marinis, F.; Simms, L.; Sugarman, K.P.; Gandara, D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol., 2008, 26, 3543-3551
8. Hirsch, F.R.; Spreafico, A.; Novello, S.; Wood, M.D.; Simms, L.; Papotti, M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J. Thorac. Oncol., 2008, 3, 1468-1481
9. Georgoulias, V.; Papadakis, E.; Alexopoulos, A.; Tsiafaki, X.; Rapti, A.; Veslemes, M.; Palmidas, P.; Vlachonikolis, I. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet, 2001, 357, 1478-1484 (Pubitemid 32488857)
10. Yousem, S.A.; Beasley, M.B. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch. Pathol. Lab. Med., 2007, 131, 1027-1032
11. Kris, M.G.; Giaccone, G.; Davies, A.; Fukuoka, M.; Garfield, D.H.; Jassem, J.; Quoix, E.A.; Sandler, A.B.; Scagliotti, G.V.; van Meerbeeck, J.P.; West, H. Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma. J. Thorac. Oncol., 2006, 1 (9 Suppl.), S32-S36. (Pubitemid 47181356)
12. West, H.L.; Crowley, J.J.; Vance, R.B.; Franklin, W.A.; Livingston, R.B.; Dakhil, S.R.; Giquere, J.K.; Rivkin, S.E.; Kraut, M.; Chansky, K.; Gandara, D.R. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann. Oncol., 2005, 16, 1076-1080 (Pubitemid 41418308)
13. Scagliotti, G.V.; Smit, E.; Bosquee, L.; O'Brien, M.; Ardizzoni, A.; Zatloukal, P.; Eberhardt, W.; Smid-Geirnaerdt, M.; de Bruin, H.G.; Dussenne, S.; Legrand, C.; Giaccone, G. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer, 2005, 50, 91-96 (Pubitemid 41297475)
14. West, H.L.; Franklin, W.A.; McCoy, J.; Gumerlock, P.H.; Vance, R.; Lau, D.H.; Chansky, K.; Crowley, J.J.; Gandara, D.R. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J. Clin. Oncol., 2006, 24, 1807-1813
15. Miller, V.A.; Riely, G.J.; Zakowski, M.F.; Li, A.R.; Patel, J.D.; Heelan, R.T.; Kris, M.G.; Sandler, A.B.; Carbone, D.P.; Tsao, A.; Herbst, R.S.; Heller, G.; Ladanyi, M.; Pao, W.; Johnson, D.H. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J. Clin. Oncol., 2008, 26, 1472-1478
16. Travis, W.D.; Brambilla, E.; Müller-Hermelink, H.K.; Harris, C.C. (Eds.). World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
17. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21, 2237-2246 (Pubitemid 46621858)
18. Kris, M.G.; Natale, R.B.; Herbst, R.S.; Lynch, T.J. Jr.; Prager, D.; Belani, C.P.; Schiller, J.H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K.S.; Cella, D.; Wolf, M.K.; Averbuch, S.D.; Ochs, J.J.; Kay, A.C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA, 2003, 290, 2149-2158 (Pubitemid 37432975)
19. Perez-Soler, R.; Chachoua, A.; Hammond, L.A.; Rowinski, E.K.; Huberman, M.; Karp, D.; Rigas, J.; Clark, G.M.; Santabarbara, P.; Bonomi, P. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol., 2004, 22, 3238-3247 (Pubitemid 41103678)
20. Hirsch, F.R.; Scagliotti, G.V.; Langer, C.J.; Varrella-Garcia, M.; Franklin, W.A. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer, 2003, 41 (Suppl. 1), S29-S42.
21. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, B.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 2005, 353, 123-132 (Pubitemid 41058344)
22. Thatcher, N.; Chang, A.; Parikh, P.; Rodrigues Pereira, J.; Ciuleanu, T.; von Pawel, J.; Thongprasert, S.; Tan, E.H.; Pemberton, K.; Archer, A.; Carroll, K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multi-centre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366, 1527-1537 (Pubitemid 41540110)
23. Cappuzzo, F. EGFR FISH versus mutation: different tests, different end-points. Lung Cancer, 2008, 60, 160-165
24. Shih, C.; Chen, V.J.; Gossetti, L.S.; Gates, S.B.; MacKellar, W.C.; Habeck L.L.; Shackelford, K.A.; Mendelsohn, L.G.; Soose, D.J.; Patel, V.F.; Andis, S.L.; Bewley, J.R.; Rayl, E.A.; Moroson, B.A.; Beardsley, G.P.; Kohler, W.; Ratnam, M.; Schultz, R.M. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res., 1997, 57, 1116-1123
25. Schultz, R.M.; Chen, V.J.; Bewley, J.R.; Roberts, E.F.; Shih, C.; Dempsey, J.A. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin. Oncol., 1999, 26 (Suppl. 6), 68-73.
26. Scagliotti, G.; Hanna, N.; Fossella, F.; Sugarman, K.; Blatter, J.; Peterson, P.; Simms, L.; Shepherd, F.A. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist, 2009, 14, 253-263
27. Peterson, P.; Park, K.; Fossella, F.; Gatzemeier, U.; John, W.; Scagliotti, G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2007, 2 (Suppl. 4), S851 (abstr. P2-328).
28. Ohe, Y.; Ichinose, Y.; Nakagawa, K.; Tamura, T.; Kubota, K.; Yamamoto, N.; Adachi, S.; Nambu, Y.; Fujimoto, T.; Nishiwaki, Y.; Saijo, N.; Fukuoka, M. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin. Cancer Res., 2008, 14, 4206-4212
29. Ciuleanu, T.; Brodowicz, T.; Zielinski, C.; Kim, J.H.; Krzakowski, M.; Laack, E.; Wu, Y.L.; Bover, I.; Begbie, S.; Tzekova, V.; Cucevic, B.; Pereira, J.R.; Yang, S.H.; Madhavan, J.; Sugarman, K.P.; Peterson, P.; John, W.J.; Krejcy, K.; Belani, C.P. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet, 2009, 374, 1432-1440
30. Gronberg, B.H.; Bremnes, R.M.; Flotten, O.; Amundsen, T.; Brunsvig, P.Fr.; Hjelde, H.H.; Kaasa, S.; von Plessen, C.; Stornes, F.; Tollali, T.; Wammer, F.; Aasebo, U.; Sundstrom, S. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 3217-3224
31. Ceppi, P.; Volante, M.; Saviozzi, S.; Rapa, I.; Novello, S.; Cambieri, A.; Lo Iacono, M.; Cappia, S.; Papotti, M.; Scagliotti, G.V. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer, 2006, 107, 1589-1596
32. Huang, C.L.; Liu, D.; Nakano, J.; Yokomise, H.; Ueno, M.; Kadota, K.; Wada, H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin. Cancer Res., 2007, 13, 6938-6946 (Pubitemid 350276873)
33. Salon, C.; Merdzhanova, G.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B. E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene, 2007, 26, 6927-6936
34. Presta, L.G.; Chen, H.; O'Connor, S.J.; Chisholm, V.; Meng, Y.G.; Krummen, L.; Winkler, M.; Ferrara, N. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res., 1997, 57, 4593-4599 (Pubitemid 27441066)
35. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med., 2006, 355, 2542-2550 (Pubitemid 44917502)
36. Reck, M.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; Archer, V.; Moore, N.; Manegold, C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol., 2009, 27, 1227-1234
37. Manegold, C.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; Archer, V.; Reck, M. A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients (PTS) with advanced or recurrent non-squamous, non-small cell lung cancer (NSCLC). Ann. Oncol., 2008, 19 (Suppl. 8), viii1 (abstr. LBA1).
38. rd; Gaudreault, J.; Damico, L.A.; Holmgren, E.; Kabbinavar, F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2004, 22, 2184-2191
39. Sandler, A.B.; Kong, G.; Strickland, D.; Johnson, D.H. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/ carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2008, 3 (Suppl.), S283 (abstr. 133).
40. Sandler, A.B.; Schiller, J.H.; Gray, R.; Dimery, I.; Brahmer, J.; Samant, M.; Wang, L.I.; Johnson, D.H. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J. Clin. Oncol., 2009, 27, 1405-1412
41. st-line treatment for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2008, 3 (Suppl.), S281 (abstr. 128).
42. Socinski, M.A.; Langer, C.J.; Huang, J.E.; Kolb, M.M.; Compton, P.; Wang, L.; Akerley, W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol., 2009, 27, 5255-5261
43. http://www.emea.europa.eu/pdfs/human/opinion/Avastin-12112009en.pdf (accessed May 3, 2009).
44. Patel, J.D.; Hensing, T.A.; Rademaker, F.; Hart, E.M.; Blum, M.G.; Treat, J.; Milton, D.T.; Bonomi, P.D. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 3284-3289
45. Waples, J.M.; Auerbach, M.; Steis, R.; Boccia, R.V.; Wiggans, R.G. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #1-04-015). J. Clin. Oncol., 2008, 26(15S), 707s (abstr 19018).
46. Scagliotti, G.V.; de Marinis, F.; Rinaldi, M.; Crinò, L.; Gridelli, C.; Ricci, S.; Zhao, Y.D.; Liepa, A.M.; Peterson, P.; Tonato, M. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial J. Thorac. Oncol., 2009, 4, 1568-1571
47. Humblet, Y. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert. Opin. Pharmacother., 2004, 5, 1621-1633 (Pubitemid 39029042)
48. Pirker, R.; Pereira, J.R.; Szczesna, A.; von Pawel, J, Krzakowski, M.; Ramalau, R.; Vynnychenko, I.; Park, K.; Yu, C.T.; Ganul, V.; Roh, J.K.; Bajetta, E.; O'Byrne, K.; de Marinis, F.; Eberhardt, W.; Gaddemeier, T.; Eming, M.; Gatzemeier, U. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373, 1525-1531
49. Cohen, B.D.; Baker, D.A.; Soderstrom, C.; Tkalcevic, G.; Rossi, A.M.; Miller, P.E.; Tengowski, M.W.; Wang, F.; Gualberto, A.; Beebe, J.S.; Moyer, J.D. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res., 2005, 11, 2063-2073
50. Karp, D.D.; Paz-Ares, L.G.; Novello, S.; Haluska, P.; Garland, L.; Cardenal, F.; Blakely, J.; Eisenberg, P.D.; Langer, C.J.; Blumenschein, G. Jr.; Johnson, F.M.; Green, S.; Gualberto, A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol., 2009, 27, 2516-2522
51. http://www.cancer.gov (accessed January 8, 2010).